Vaccines for an influenza pandemic: scientific and political challenges
Open Access
- 1 March 2007
- journal article
- review article
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 1 (2) , 55-60
- https://doi.org/10.1111/j.1750-2659.2007.00011.x
Abstract
So far, most published results from clinical trials using various avian influenza virus vaccine formulations have been disappointing. Should the pandemic strike, we still do not have the ability to provide an efficacious pandemic vaccine in time and in sufficient quantities for the world. The H5N1 enzootic could potentially give rise to a pandemic at any time. Transcontinental air traffic could seed the pandemic virus to most corners of the globe within a few weeks/months. We still have a unique window of opportunity to stimulate and support academia and the pharmaceutical industry to accelerate the urgently needed vaccine research. The political inertia is surprising, particularly as politicians, if and when a pandemic eventuates, will be asked why, despite repeated warnings, they did not take appropriate action in time. It is a governmental obligation--and not that of the WHO or the pharmaceutical industry--to protect their nationals. Moreover, when the poorer nations of this world realize that equitable quantities of the scarce supplies of vaccines, drugs and medical essentials will not come their way, the post-pandemic international scene will be one of even more deep distrust for many years. This scenario is not acceptable.Keywords
This publication has 52 references indexed in Scilit:
- Antibody responses after dose-sparing intradermal influenza vaccinationVaccine, 2007
- Emergence and predominance of an H5N1 influenza variant in ChinaProceedings of the National Academy of Sciences, 2006
- Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptorsNature, 2006
- Low Frequency of Poultry-to-Human H5N1 Transmission, Southern Cambodia, 2005Emerging Infectious Diseases, 2006
- Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult VolunteersJournal of Virology, 2006
- Anticipating crisis: Towards a pandemic flu vaccination strategy through alignment of public health and industrial policyVaccine, 2005
- Avian Influenza A (H5N1) Infection in HumansNew England Journal of Medicine, 2005
- Clinical experience with inactivated, virosomal influenza vaccineVaccine, 2005
- Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titersVirus Research, 2004
- Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic useVirus Research, 2004